School of Humanities and Management, Guangdong Medical University, Dongguan, 523808, China.
Institute of Health Law and Policy, Guangdong Medical University, Dongguan, 523808, China.
Health Qual Life Outcomes. 2023 Nov 29;21(1):128. doi: 10.1186/s12955-023-02205-y.
The present study is aimed to develop and validate a quality of life scale for systemic lupus erythematosus (SLE) patients with Chinese cultural background, QLICD-SLE (V2.0).
The QLICD-SLE (V2.0) was developed using a systematic approach that involved focus groups, nominal discussions, and pilot testing. A total of 428 SLE patients participated in the scale's assessment. Validity was examined through qualitative analysis, item domain correlation, multidimensional scaling, and factor analysis. Reliability was assessed using Pearson's correlation and Cronbach's alpha coefficients. To evaluate responsiveness, paired T-tests were conducted to compare pre- and post-treatment measurements with the standardised response mean (SRM) being calculated.
Correlation and factor analyses demonstrated strong construct validity. When using SF-36 as criteria, the correlation between various domains of QLICD-SLE and SF-36 ranged from 0.55 to 0.70. Test-retest correlation coefficients exceeded 0.71, and Cronbach's alpha coefficients for both measurements in each domain were greater than or equal to 0.75. T-test results showed that both the overall score and most facet scores within each domain showed statistically significant changes after treatment (P < 0.05), indicating reasonable responsiveness.
The QLICD-SLE (V2.0) appears to be a valid and reliable instrument for assessing the quality of life in patients with SLE.
本研究旨在为具有中国文化背景的系统性红斑狼疮(SLE)患者开发和验证一种生活质量量表,即 QLICD-SLE(V2.0)。
采用系统方法开发 QLICD-SLE(V2.0),包括焦点小组、名义讨论和试点测试。共有 428 名 SLE 患者参与了该量表的评估。通过定性分析、项目域相关性、多维标度和因子分析来检验有效性。使用 Pearson 相关系数和克朗巴赫α系数评估可靠性。为了评估反应性,进行了配对 T 检验,以比较治疗前后的测量值,并计算标准反应均值(SRM)。
相关性和因子分析表明具有较强的结构有效性。当使用 SF-36 作为标准时,QLICD-SLE 各领域与 SF-36 的相关性范围为 0.55 至 0.70。测试-重测相关系数超过 0.71,并且每个领域的两次测量的克朗巴赫α系数均大于或等于 0.75。T 检验结果表明,治疗后,总体评分和各领域的大多数方面评分均有统计学意义上的显著变化(P < 0.05),表明具有合理的反应性。
QLICD-SLE(V2.0)似乎是一种有效的、可靠的评估 SLE 患者生活质量的工具。